Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares shot up 2.7% on Monday . The stock traded as high as $96.45 and last traded at $96.42, with a volume of 987,389 shares changing hands. The stock had previously closed at $93.89.

Several brokerages have recently weighed in on VRTX. Robert W. Baird reissued an “outperform” rating and set a $128.00 price target (down previously from $144.00) on shares of Vertex Pharmaceuticals in a research report on Sunday, May 1st. Stifel Nicolaus lowered their price target on shares of Vertex Pharmaceuticals from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 1st. Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, April 28th. BMO Capital Markets began coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, April 7th. They set a “market perform” rating and a $90.00 price target on the stock. Finally, Jefferies Group reissued a “buy” rating and set a $116.00 price target on shares of Vertex Pharmaceuticals in a research report on Sunday, March 27th. Eight investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $123.11.

The stock’s 50-day moving average price is $89.11 and its 200 day moving average price is $88.26. The firm’s market capitalization is $23.69 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, April 27th. The pharmaceutical company reported $0.09 EPS for the quarter, missing the Zacks’ consensus estimate of $0.29 by $0.20. The business earned $398.10 million during the quarter, compared to analysts’ expectations of $439.94 million. The business’s revenue was up 187.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.62) EPS. On average, analysts anticipate that Vertex Pharmaceuticals Inc. will post $1.02 EPS for the current fiscal year.

In other news, Director Joshua S. Boger sold 5,130 shares of the stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $81.02, for a total value of $415,632.60. Following the transaction, the director now owns 270,414 shares of the company’s stock, valued at approximately $21,908,942.28. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Joshua S. Boger sold 6,500 shares of the stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $90.33, for a total value of $587,145.00. Following the completion of the transaction, the director now directly owns 274,725 shares in the company, valued at approximately $24,815,909.25. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of the stock. Robeco Institutional Asset Management B.V. increased its position in Vertex Pharmaceuticals by 32.1% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 10,728 shares of the pharmaceutical company’s stock worth $1,350,000 after buying an additional 2,605 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Vertex Pharmaceuticals by 2.1% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,054 shares of the pharmaceutical company’s stock worth $2,020,000 after buying an additional 335 shares during the period. Gulf International Bank UK Ltd increased its position in Vertex Pharmaceuticals by 3.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 72,092 shares of the pharmaceutical company’s stock worth $9,071,000 after buying an additional 2,100 shares during the period. Mutual of America Capital Management LLC increased its position in Vertex Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 32,865 shares of the pharmaceutical company’s stock worth $4,135,000 after buying an additional 173 shares during the period. Finally, Morgan Stanley increased its position in Vertex Pharmaceuticals by 57.0% in the fourth quarter. Morgan Stanley now owns 309,826 shares of the pharmaceutical company’s stock worth $38,986,000 after buying an additional 112,441 shares during the period.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.